**CLAIMS**

1. The use of a recombinant modified Vaccinia Ankara (MVA) virus for the manufacture of a medicament for inducing a robust CD8 T cell response against a neoantigen in a human;

wherein the recombinant MVA comprises a Pr13.5 promoter operably linked to a nucleotide sequence encoding the neoantigen,

wherein the Pr13.5 promoter comprises 2 copies of a nucleotide sequence of at least 40 nucleotides that has 100% identity with SEQ ID NO:1

wherein the 2 copies of the nucleotide sequence are separated by 20-80 nucleotides.

2. The use of claim 1, wherein the 2 copies of the nucleotide sequence are separated by 30-40 nucleotides.

3. The use of claim 1, wherein the 2 copies of the nucleotide sequence are separated by 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

4. The use of claim 1, wherein each of the 2 copies of the nucleotide sequence comprises 44 nucleotides having 100% identity with SEQ ID NO:1.

5. The use of claim 1, wherein the Pr13.5 promoter comprises SEQ ID NO:2.

6. A recombinant modified Vaccinia Ankara (MVA) virus comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding a neoantigen,

wherein the Pr13.5 promoter comprises 2 copies of a nucleotide sequence of at least 40 nucleotides that has 100% identity with SEQ ID NO:1

wherein the 2 copies of the nucleotide sequence are separated by 20-80 nucleotides.

7. The recombinant MVA of claim 6, wherein the 2 copies of the nucleotide sequence are separated by 30-40 nucleotides.

8. The recombinant MVA of claim 6, wherein the 2 copies of the nucleotide sequence are separated by 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

9. The recombinant MVA of claim 6, wherein each of the 2 copies of the nucleotide sequence comprises 44 nucleotides having 100% identity with SEQ ID NO:1.

10. The recombinant MVA of claim 6, wherein the Pr13.5 promoter comprises SEQ ID NO:2.

11. A recombinant modified Vaccinia Ankara (MVA) virus for use in therapy or prophylaxis, said recombinant MVA comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding a neoantigen,

wherein the Pr13.5 promoter comprises 2 copies of a nucleotide sequence of at least 40 nucleotides that has 100% identity with SEQ ID NO:1

wherein the 2 copies of the nucleotide sequence are separated by 20-80 nucleotides.

12. The recombinant MVA for use of claim 11, wherein the 2 copies of the nucleotide sequence are separated by 30-40 nucleotides.

13. The recombinant MVA for use of claim 11, wherein the 2 copies of the nucleotide sequence are separated by 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

14 The recombinant MVA for use of claim 11, wherein each of the 2 copies of the nucleotide sequence comprises 44 nucleotides having 100% identity with SEQ ID NO:1.

15. The recombinant MVA for use of claim 11, wherein the Pr13.5 promoter comprises SEQ ID NO:2.